Table 1.
Baseline characteristics
| Treatment: 100 mg + 200 mg | Treatment: 200 mg + 100 mg | All subjects | |
|---|---|---|---|
| N | 6 | 6 | 12 |
| Age (years) | |||
| Mean (SD) | 49.3 (13.7) | 29.5 (5.8) | 39.4 (14.4) |
| Sex, N (%) | |||
| Women | 3 (50.0) | 4 (66.7 ) | 7 (58.3) |
| Men | 3 (50.0) | 2 (33.3 ) | 5 (41.7) |
| Race, N (%) | |||
| Caucasian | 6 (100.0) | 6 (100.0) | 12 (100.0) |
| Height (m) | |||
| Mean (SD) | 1.74 (0.1) | 1.72 (0.1) | 1.73 (0.1) |
| Weight at baseline (kg) | |||
| Mean (SD) | 79.0 (19.3) | 65.0 (13.4) | 72.0 (17.4) |
| Body mass index at baseline (kg/m2) | |||
| Mean (SD) | 25.9 (6.1) | 21.8 (1.8) | 23.8 (4.8) |
| Hemoglobin (mmol/L) | |||
| Mean (SD) | 8.1 (0.4) | 8.0 (0.9) | 8.1 (0.7) |
| S-ferritin (μg/L) | |||
| Mean (SD) | 73.2 (53.1) | 65.8 (48.2) | 69.8 (48.5) |
| Transferrin saturation (%) | |||
| Mean (SD) | 18.6 (6.7) | 12.7 (7.8) | 15.4 (7.6) |
| C-reactive protein (mg/L) | |||
| Mean (SD) | 3.5 (3.8) | 7.0 (8.1) | 5.2 (6.3) |